Evolutionary and Structural Constraints Define a Mutation-Resistant Catalytic Core in E. coli Serine Hydroxy methyltransferase (SHMT)

TL;DR

This study reveals that E. coli SHMT has a highly conserved, structurally rigid catalytic core with low mutational tolerance, making it a promising target for new antibacterial drugs due to its resistance to mutation.

Contribution

The paper introduces a comprehensive multi-scale computational framework to characterize the structural and evolutionary constraints of SHMT, highlighting its potential as an antibiotic target.

Findings

SHMT's catalytic core is highly conserved and tightly coupled.

Active site exhibits extreme structural rigidity and low mutational tolerance.

Compared to other folate pathway enzymes, SHMT is more evolutionarily constrained.

Abstract

Serine hydroxymethyltransferase is an essential enzyme in the Escherichia coli folate pathway, yet it has not been adopted as an antibacterial target, unlike DHFR, DHPS, or thymidylate synthase. To investigate this discrepancy, we applied a multi-scale computational framework that integrates large-scale sequence analysis of 1000 homologs, coevolutionary interaction mapping, structural community analysis, intrinsic disorder profiling, and adaptive fitness modelling. These analyses converge on a single conclusion: the catalytic core of SHMT forms an exceptionally conserved and tightly coupled structural unit. This region exhibits dense coevolution, strong intramolecular connectivity, minimal disorder, and extremely low mutational tolerance. Peripheral loops and termini, in contrast, are far more flexible. Relative to established folate-pathway antibiotic targets, SHMT active site is even more rigid and evolutionarily constrained. This extreme constraint may limit the emergence of resistance-compatible mutations, providing a plausible explanation for the absence of natural-product inhibitors. Fitness trajectory modelling supports this interpretation, showing that nearly all active-site residues tolerate only rare or neutral substitutions. Together, these findings identify SHMT as a structurally stable and evolutionarily restricted enzyme whose catalytic architecture is unusually protected. This makes SHMT an underexplored yet promising target for the rational design of next-generation antibacterial agents.